mercy of the marketplace, [3] randomized controlled trials (RCTs) should be used more widely.
Although RCTs are considered the best design when evaluating the efficacy of orthodontic treatments, not all RCTs meet the minimum requirements for validity. That is, not all randomized, controlled, prospective trials are of good quality to be counted as valid evidence. For example, even a properly designed and executed RCT shows inadequate reporting of the quality and quantity of harms and applicability to everyday practice. [4] RCTs should address both benefits and harms. Benefits have always been accorded greater prominence when reporting trials, with little effort to balance assessments of both, which can mislead clinicians. Generally, critical readers have assumed that if something is not mentioned, it likely did not happen. To enhance the practice of evidence-based orthodontic care, trialists need to pay closer attention to rigorous implementation and reporting of important methodological safeguards against bias.
In this article, I will discuss the basic concepts and design of RCTs followed by the issues to be faced when designing a study with some examples on how to overcome them.
First, there are some basic concepts that I would like to explain,
RandoMizaTion
The strength of the randomized trial is based on the aspects of design that eliminate various types of bias. Randomization ensures that each patient has an equal chance of receiving any of the treatments under study. This creates groups that are alike in all aspects except for the intervention that each group receives. So, how do we do this? This involves generation of randomization schedule by obtaining the random numbers and assigning them to each subject. For simple studies, randomization can be performed using random number tables and assigning them to treatment conditions. However, for large studies or when stratification is needed, it is better to use a computer programming such as statistical analysis software (SAS). SAS Institute Inc., Cary, NC, USA., to use the randomization. In the Dynamax study [1] we used computer generated random numbers with stratification on gender to get an equal number of males and females between groups.
sTRaTificaTion
Stratification prior to randomization is carried out to prevent imbalances between treatment arms in factors that may strongly influence treatment outcomes (covariates). This improves power for smaller trials and lowers the occurrence of Type I error. [5] Common stratification characteristics are age, gender, race, and hospital/clinic. It is also important to avoid creating too many strata [6] as this would result in the ratio of strata to sample size being too large with many strata never being filled or having just a few patients. Strata should be carried out only to those known to be strongly associated with outcome.
allocaTion concealMenT
Allocation concealment is an essential aspect of a randomized trial. The idea is that the person who generates the allocation sequence should not be the person who determines eligibility and entry of patients. If this is not carried out properly, there is a possibility that those responsible for recruiting participants could detect the upcoming treatment assignments and then channel individuals with a better prognosis to the experimental group and those with a poorer prognosis to the control group, or vice versa.
The best ways of allocation concealment are:
• Sealed opaque envelope system: In this, participating clinicians are given randomly generated treatment allocations within sealed opaque envelopes. However, this has proved inferior to the other systems [7] • Distance randomization over central telephone system: Here, patient details are supplied, eligibility confirmed, and the patient entered into the trial before the treatment allocation is divulged. This method was used in the Dynamax study [1] • Distance randomization over the internet: The investigator uses the internet to load the basic patient details and the randomization is performed by a central computer operated system. This method was used in the Temporary anchorage device study.
[8]
Blinding
The term blinding refers to keeping trial participants, investigators (usually healthcare providers), or assessors (those collecting outcome data) unaware of an assigned intervention so that they are not influenced by that knowledge. Where possible, blinding should be followed to prevent ascertainment bias and protect the sequence after allocation. Blinding could be of three different types.
• The term single-blinded trial means one of the three categories of individuals (participant, investigator, or assessor) remain unaware of intervention assignments throughout the trial • A double-blind trial is one in which the participants and the investigators are unaware of the intervention assignments throughout the trial • Triple-blinded trial usually refers to a double-blind trial that also maintains a blind data analysis.
Although blinding represents an important, distinct aspect of randomized trials, it might prove difficult or impossible in certain trials. For example, in the early Class II trial, it was impossible to blind the clinicians and patients. [9] However, the assessors were blinded and hence, it was a single-blinded study.
inTenTion-To-TReaT
Intention-to-treat (ITT) includes all randomized patients in the groups to which they were randomly assigned, regardless of their adherence to the entry criteria, regardless of the treatment they actually received, and regardless of subsequent withdrawal from treatment or deviation from the protocol. It is the process of using every subject who was randomized according to randomized treatment assignment in the analysis. In simpler terms, it means, "as randomized, as analyzed." It ignores protocol deviations, noncompliance, dropouts, and anything that happens after randomization. If ITT is not carried out, the clinical effectiveness of the trial will be overestimated. The idea of ITT gives a pragmatic estimate rather than a potential benefit in patients who receive treatment as planned.
The other type of analysis is "per protocol." In this, participants are included only if they have received and completed the intended treatment in accordance with the protocol. However, this type of analysis often exaggerates effect estimates of the outcome assessed. [10, 11] daTa MoniToRing coMMiTTee
The data monitoring committee (DMC) is a group of independent experts external to a study who assess the progress, safety data, and if needed critically evaluate the endpoints of a clinical study. They are appointed to (i) safeguard the interests of trial's participants, potential participants, investigators, and sponsor, (ii) assess the safety and efficacy of the trial's interventions, and (iii) monitor the trial's overall conduct, and protect its validity and credibility. The DMC also has the responsibility of deciding whether or not to close the study on the basis of predetermined early stopping rules that relate to harms or outcome. To do so, a DMC may review unblinded study information (on a patient level or treatment group level) during the conduct of the study. This is the only time when the randomization code can be broken before the final data analysis. Based on its review, the DMC provides the sponsor with recommendations regarding study modification, continuation, or termination. The Dynamax trial is a good example; the DMC, after an interim analysis, advised the trial investigators to stop the trial as the Dynamax group patients suffered significantly more problems compared to the Twin-block group patients. [1] sToPPing Rule A part of good research practice is to have predefined statistical stopping boundaries documented before the start of the trial. This is to avoid preventing undue risk (harms) to participants. For example, the Dynamax trial [9] was stopped due to several breakages and soft tissue trauma that patients suffered from the Dynamax appliance. The other reasons are (i) stopping a trial for benefit, i.e. the intervention group showing unrealistically large treatment effects or (ii) stopping a trial for futility. In this case, it becomes necessary to stop a trial, as the difference between the treatment groups during the interim analysis is so unimpressive that it is unlikely that the final analysis will show any difference. That is, it is not justifiable in terms of time, money, and effort.
The concepts of statistical stopping guidelines as defined by Pocock are: [12] • A sufficiently small P value for treatment difference on a trial's primary endpoint can be a guideline for when it is ethically desirable to stop a trial • With several repeated interim analyses looking at the accumulating data, we need to guard against an excessive risk of a false positive result. This requires smaller P values than the conventional 0.05 level • Though the early sequential methodology is related to continuous monitoring of the gradually accumulating data, "it is usually more acceptable to adopt a 'group sequential' approach with a limited number of preplanned interim analyses before each DMC meeting."
The design of an RandoMized conTRolled TRial
Understanding the principles behind RCT enables appreciation of the reliability and validity of the results. An 
S45
appropriate design with emphasis on all the above-mentioned criteria reduces the chance for errors and increases the ability to draw valid conclusions from the trial. In the following section, I will explain how to design a simple parallel two arm RCT.
The basic framework for conducting an RCT is fairly simple. You approach a sample population and consent patients for taking part in a trial. The consented subjects are then randomly assigned to one of the two groups, one group is the intervention you would like to test, and the other group is either an untreated control or conventional treatment (acting as control). The changes are then measured over a period of time to see if there are any differences between the groups in outcome. The method we used in the Dynamax study is shown below. [1] Although this looks fairly simple, designing and conducting an RCT is a more intensive process. The following steps are to be followed for conducting a good quality RCT.
The research question
A research question guides and centers your research. It should be simple and clear. A good study is one that has one question with one hypothesis. The question that we used in the bonding study was "Does self-etching primer have more bracket failures than conventional etch and primer?" [13] The study was powered to test the difference in bracket failure rates between the groups.
Having multiple research questions (and multiple hypotheses) introduces Type I error that occurs when statistical tests are used repeatedly. Type I error, also known as "false positive," is the error of rejecting a null hypothesis when it is actually true. In simple words, it occurs when we observe a statistical difference when in fact there is not any. A common example in orthodontics is when statistical tests are carried out for several cephalometric variables. [14] Developing a protocol This is the key for a good study. A good protocol is when study objectives and methods are clearly thought through and described. The protocol should be developed in collaboration with statisticians, investigators, other members of the research team, necessary regulatory authorities, and the sponsors (funding body). It is also essential that the participants (patients) are involved in the development of the protocol. For example, in the TADs trial, a focus group meeting with patients and parents helped us to develop the quality of life questionnaire. [8] This is now mandatory for most funding organizations.
Applying for funding
Once the protocol is developed and agreed by the research group, and the costing process complete, the chief investigator can apply for funding. While completing the costing process, it is important to consider trial management costs (trial monitoring, data management, statistician, DMC, etc.,) in addition to materials and estates.
Trial documentation
Prior to applying for ethical approval, all necessary documentations including investigators brochure, adverse events reporting form, and standard operating protocols (SOPs) should be in place. The SOPs are detailed instructions on the trial that help to maintain uniformity. They help researchers maintain quality control and ensure compliance with the local policies. These are audited to make sure that the trial follows the written instructions. Therefore, they have to be written in a manner that gives good detail on how the research and clinical work is performed.
Ethical approval
All clinical trials require a favorable opinion from the Ethics Committee (local or national). The chief investigator is responsible for obtaining the ethical approval. Research projects must also be approved by the host organization.
Trial registration
International bodies such as the revised declaration of Helsinki and the World Health Organization require registration of a clinical trial in a publicly accessible registry before commencing patient recruitment. This is important not only for transparency, but also to facilitate collaborative efforts between researchers working on similar topics. It is also a requirement for the member journals of the International Committee of Medical Journal Editors for trials to be registered prior to commencement. The websites that allow registry free of charge are: The US National Institute of Research (https://clinicaltrials.gov) and the International Standard RCT Number Register (http://isrctn.org). The Dynamax trial (NCT00957489) and the TADs trial (NCT00995436) were registered with the former database.
Managing a trial
The following flowchart gives an overview for conducting a randomized trial: To guarantee the quality of the study, it is important for trials to undergo quality assurance process. This is an ongoing process. manager to review data in a timely manner to allow them to be corrected. In a clinical trial, it is inevitable to have some missing data, but close monitoring could minimize them to a great extent.
Data analysis
Data analysis should only be carried out at the end of the study, except in cases where the interim analysis is planned at the start of the study. The statistical tests will depend on the research question, the methodology, and the type of data collection. There are several software packages such as (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0.Armonk, NY: IBM Corp.) and SAS that can be used for data analysis. The following table can be used as a guide for performing basic statistics.
There are two ways to analyze data (i) ITT: Analyze all persons randomized, regardless of their adherence with the entry criteria, regardless of the treatment they actually received, and regardless of subsequent withdrawal from treatment or deviation from the protocol, and (ii) per protocol: Analyze only those who complete treatment. The latter analysis is potentially biased, and therefore, researchers must use ITT to ensure the validity of the results. [15] 
Dissemination
There is an ethical responsibility for research findings to be accessible. This is important to ensure the work is transparent and open to scrutiny and also for the development of knowledge in the field. There are several methods for dissemination, including journals, conference presentations, websites, and exhibitions. Researchers should aim to publish their research in open access journals as this enhances the visibility and impact of the study.
The challenges
Although RCTs are considered "gold standard" for proof of efficacy, there are several challenges in conducting a good quality RCT. Some of the challenges are described below.
Manpower and time
RCTs are not quick. They are time consuming. It may take years before the results are available for analysis. For example, the UK Class II study [9] was conducted over 10 years and the TADs study [8] took more than 5 years. RCTs also require a lot of manpower. In the previous section, I explained the need for having a research assistant and a trial manager for quality assurance. In addition, a statistician and a research nurse are vital, along with site investigators (usually clinicians). A good study will need excellent coordination between the site investigators and the trial management team. In the TAD study, we had a chief investigator, two principal investigators, a trial manager, a statistician, and a research assistant. [8] Cost This is one of the major limiting factors for conducting an RCT. A well conducted RCT is expensive. A number of reasons are behind this. (i) The need for a large number of participants in a trial to ensure sufficient statistical power. This is, especially true for orthodontic trials where the outcome assessed is usually small in magnitude, but is still deemed clinically significant (ii) the duration of follow-up. General orthodontic trials that look at data from start to the end of orthodontic treatment will run for at least 5 years, and (iii) the low incidence/prevalence of malocclusion. The Class II Division 2 trial is a good example where the recruitment was so difficult and unachievable. One way to keep the cost down is to carry out a simple, single, easily assessed outcome measure.
Recruitment
Another limiting factor for RCT is recruitment. This is even more of an issue for orthodontic trials as the prevalence of some of the malocclusion is very low. For example, the multi-center Class II Division 2 trial [16] was abandoned due to difficulty in recruiting participants.
Ethical issue
This is one of the commonly mentioned problems with RCTs. Some RCTs may involve denying treatment to people who need it. The Clinical staffs who are involved in recruitment find this extremely difficult. For example, in the Class II Division 2 study, [16] the two arms were extraction and nonextraction treatment. It was increasingly difficult for clinicians to recruit patients as this will mean that there is a 50% chance that their teeth will be extracted when there is an option of nonextraction treatment.
Dropouts
Although most of the orthodontic trials manage to have low dropout rates, this is still an area of concern. This is, especially true in long-term orthodontic studies or two phase studies. In the UK Class II trial, [9] a dropout rate of 23% was observed, which can be argued as due to the length of the study. However, a study with higher dropout rate is considered as having a high risk of bias. Hence, it is important to monitor closely for missing data and allow them to be corrected in a timely manner. As I mentioned previously, some missing data is inevitable, but all steps need to be taken to minimize them as much as possible.
Validity
A significant drawback with RCTs is that it is hard to generalize the results. RCTs generally have high internal validity, but at the expense of external validity. The results may only be applicable to a particular group of people in that context. This means that the intervention may not work in the same way for a different group in a different context. When using the evidence for our patients in clinical practice, we need to ask this simple question "is the research generalizable?" and "are the results applicable to this patient?" suMMaRy RCTs are quite credibly the "gold standard." If other methods are used, it should only be in situations where RCTs are too expensive or otherwise impractical. Although it may take more effort to design and more money to run RCTs, it is essential for high quality RCTs to be carried out to test the claims of manufacturers of new and existing products in the orthodontic field and keep our patients safe.
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